Edwards Lifesciences Corporation (BVMF:E1WL34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 262.78B +12.2% |
| Revenue (ttm) | 33.74B +14.6% |
| Net Income | 5.21B -75.8% |
| EPS | 8.91 -75.5% |
| Shares Out | n/a |
| PE Ratio | 50.47 |
| Forward PE | 28.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8 |
| Open | 113.96 |
| Previous Close | 110.99 |
| Day's Range | 113.96 - 113.96 |
| 52-Week Range | 94.30 - 122.51 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 23, 2026 |
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial numbers in USD Financial StatementsNews
Edwards Lifesciences Transcript: Deutsche Bank 2026 Healthcare Summit
The summit highlighted a clear focus on structural heart disease, with regulatory changes expanding TAVR access and multi-year growth opportunities. Innovation in product lines and clinical trials, especially in TMTT, supports ambitious revenue targets, while disciplined capital allocation and global expansion remain priorities.
Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacemen...
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive off...
Edwards Lifesciences beats quarterly estimates on strong demand for heart devices
Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending i...
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
Edwards Lifesciences Earnings Call Transcript: Q2 2026
Q2 sales grew 12.5% year-over-year, driven by strong TAVR and TMTT performance, leading to raised 2026 sales guidance and reaffirmed EPS outlook. Robust adoption of innovative therapies and favorable market dynamics support confidence in long-term 10% average sales growth.
Edwards Lifesciences Earnings release: Q2 2026
Edwards Lifesciences released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q2 2026
Edwards Lifesciences has published its Q2 2026 quarterly earnings report on July 23, 2026.
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant curren...
Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host ...
Edwards' Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which ...
Pacific Defense Launches Dual-Enclave 100G Ethernet Switch for Secure Multi-Mission C5ISR and Electronic Warfare Systems
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, determinis...
East West Announces $858,000 Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, ...
Edwards Lifesciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results and increased guidance reflect broad-based growth in TAVR, surgical, and TMTT segments, supported by new clinical evidence and product innovation. Leadership changes and a robust pipeline position the company for sustained double-digit growth and margin improvement through 2027 and beyond.
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Edwards Lifesciences Announces Appointment of CFO
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (...
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its propriet...
Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chi...
Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares up over 4% in exte...
Edwards Lifesciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 12.7% sales growth, driven by strong TAVR, TMTT, and Surgical performance, prompting raised full-year guidance for sales and EPS. Robust clinical evidence, innovation, and favorable market dynamics support continued growth across all segments.
Edwards Lifesciences Earnings release: Q1 2026
Edwards Lifesciences released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q1 2026
Edwards Lifesciences has published its Q1 2026 quarterly earnings report on April 23, 2026.
Edwards Lifesciences Reports First Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, co...
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will hos...